Vaccine shows promise against typhoid and invasive Salmonella in first human trial

The University of Maryland School of Medicine has successfully completed a Phase I clinical trial of a vaccine against typhoid fever and invasive Salmonella, showing promising results in combating these serious infections.

• The Phase I clinical trial involved 40 healthy adults who received varying doses of the vaccine or a placebo, assessing safety and immune response against typhoid and invasive Salmonella.
• Results indicated a strong immune response in participants, with no serious adverse effects reported, highlighting the vaccines potential for widespread use against these bacteria.
• Typhoid fever and invasive Salmonella are significant global health threats, causing millions of infections annually, underscoring the urgent need for effective vaccines.